eczema, and other inflammatory conditions in some adults and children. Dupixent comes in two forms: pens and syringes. Each pen or syringe is prefilled with a single dose of Dupixent. Your doctor ...

Dupixent and Adbry are FDA approved only for the atopic dermatitis form of eczema. It is possible, however, that healthcare providers might also prescribe these medicines off-label for other types ...

In relapsing forms of the disease it offers ... New option for eczema patients Meanwhile, Sanofi and Regeneron's Dupixent is a new option for people with moderate-to-severe atopic dermatitis ...

Dupixent (dupilumab) for chronic obstructive pulmonary disease: The monoclonal antibody, already approved for eczema ... first approved in a nasal spray form. It will be available for the 2025-26 ...

The use of Sanofi’s Dupixent in atopic dermatitis has set a high benchmark for competitors within the space. Credit: marishkaSm via Shutterstock. Sanofi’s participation at the JP Morgan 43rd Annual ...

NICE had previously rejected Roche's Ocrevus (ocrelizumab) for multiple sclerosis and Sanofi's Dupixent (dupilumab) for eczema – scientific ... adults with relapsing forms of multiple sclerosis ...

The Albanese Government has ensured thousands of Australians living with severe eczema will continue to have access to affordable treatments. Dupixent is a highly effective treatment for severe eczema ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.